That means fewer highs and lows, less mindless snacking, and a more stable, in-control feeling throughout the day
According to NICE guideline NG28, GLP-1 receptor agonists should be considered when: Triple therapy (metformin and two other oral drugs) is not effective, not tolerated, or contraindicated The patient has a BMI 35 kg/m (or lower in people of Black, Asian and other minority ethnic groups) and specific obesity-related comorbidities The patient has a BMI 40% reduction in non-HDL cholesterol GLP-1 receptor agonist for glycaemic control and weight management (with secondary lipid benefits) Ezetimibe if non-HDL cholesterol reduction is insufficient Lifestyle interventions addressing diet, exercise, and weight Monitoring and follow-up are essential components of cholesterol management
In the retatrutide trials, the ratio of fat loss to lean loss was favorable compared to caloric restriction alone, where lean mass can represent 25-35% of total weight lost
Endocrinology Targeting the central melanocortin system for the treatment of metabolic disorders 2023 DOI: 10.1038/s41574-023-00855-y PMID: 37365323 Sweeney P, Gimenez LE, Hernandez CC, et al
Why did some telehealth platforms stop offering tirzepatide in 2024
This may result in you starting at a lower strength to reduce the potential impact of side effects and facilitate a safe transition